Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer

MLA

Drögemöller, Britt I., et al. “Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.” JAMA Oncology, vol. 3, no. 11, Nov. 2017, pp. 1558–62. EBSCOhost, https://doi.org/10.1001/jamaoncol.2017.0502.

APA

Drögemöller, B. I., Monzon, J. G., Bhavsar, A. P., Borrie, A. E., Brooks, B., Wright, G. E. B., Liu, G., Renouf, D. J., Kollmannsberger, C. K., Bedard, P. L., Aminkeng, F., Amstutz, U., Hildebrand, C. A., Gunaretnam, E. P., Critchley, C., Chen, Z., Brunham, L. R., Hayden, M. R., Ross, C. J. D., … Carleton, B. C. (2017). Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. JAMA Oncology, 3(11), 1558–1562. https://doi.org/10.1001/jamaoncol.2017.0502

Chicago

Drögemöller, Britt I., Jose G. Monzon, Amit P. Bhavsar, Adrienne E. Borrie, Beth Brooks, Galen E. B. Wright, Geoffrey Liu, et al. 2017. “Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.” JAMA Oncology 3 (11): 1558–62. doi:10.1001/jamaoncol.2017.0502.